Glenmark Pharma rises on receiving marketing approval for Ryaltris in 13 EU and UK nations

Post this approval, the pharmaceutical company shall launch Ryaltris directly in the markets of the Czech Republic, Slovakia, Poland, and the UK.

Glenmark Pharmaceuticals Limited, a leading pharmaceutical company, announced this morning that it has received marketing approval for Ryaltris, a fixed-dose combination nasal spray in 13 countries across the EU and UK.  

Post this approval, the pharmaceutical company shall launch Ryaltris directly in the markets of the Czech Republic, Slovakia, Poland, and the UK. In the rest of Europe, the marketing will be done by the Menarini Group as part of its exclusive licensing agreement with Glenmark. Furthermore, for the commercialization of Ryaltris in the US and Canada, the company has collaborated with Hikma Pharmaceuticals PLC and Bausch Health respectively. 

The approved formulation- Ryaltris, helps relieve symptoms of allergic rhinitis, which includes the stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes. It is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children above 12 years of age.  

Owing to this development, at 12.06 pm, the share price of Glenmark Pharmaceuticals Limited was up by 1.3 per cent, trading at Rs 515.85 as against the previous day’s closing price of Rs 509.2 on BSE.